Status:
COMPLETED
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated w...
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Histologically confirmed, relapsed or refractory SCLCr
- Aged 18 or over and a life expectancy of more than 2 months
Exclusion
- Any evidence of clinically active interstitial lung disease
- Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00298688
Start Date
September 1 2004
End Date
March 1 2007
Last Update
June 12 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Copenhagen, Denmark
2
Research Site
Herlev, Denmark
3
Research Site
Manchester, United Kingdom